Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naphak Modhiran

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Nature Communications|June 16, 2023
Structure and antigenicity of divergent Henipavirus fusion glycoproteinsAriel Isaacs, Yu Shang Low, Kyle L Macauslane, et al.
Frontiers in Microbiology|March 1, 2021
An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2Alberto A Amarilla, Naphak Modhiran, Yin Xiang Setoh, et al.
Journal of Medical Virology|October 13, 2025
Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022)Rhys H Parry, Yingjun Shang, Julian D J Sng, et al.
Environmental Research|March 1, 2021
Assessing the potential of unmanned aerial vehicle spraying of aqueous ozone as an outdoor disinfectant for SARS-CoV-2Simon Albert, Alberto A Amarilla, Ben Trollope, et al.
Nature Communications|September 26, 2025
A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicitySumma Bibby, James Jung, Yu Shang Low, et al.
Nature Communications|November 5, 2025
Author Correction: A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicitySumma Bibby, James Jung, Yu Shang Low, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Development and evaluation of an <sup>18</sup>F-labeled nanobody to target SARS-CoV-2's spike proteinSara Lopes van den Broek, Rocío García-Vázquez, Ida Vang Andersen, et al.
NPJ Vaccines|November 9, 2021
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A virusesChristopher L D McMillan, Stacey T M Cheung, Naphak Modhiran, et al.
Plos Pathogens|July 17, 2025
A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirusAndrew Young, Sharada Kolekar, Carlos Alvarez Mendoza, et al.
NPJ Vaccines|January 6, 2022
Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A virusesChristopher L D McMillan, Stacey T M Cheung, Naphak Modhiran, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Nature Communications|June 16, 2023
Structure and antigenicity of divergent Henipavirus fusion glycoproteinsAriel Isaacs, Yu Shang Low, Kyle L Macauslane, et al.
Frontiers in Microbiology|March 1, 2021
An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2Alberto A Amarilla, Naphak Modhiran, Yin Xiang Setoh, et al.
Journal of Medical Virology|October 13, 2025
Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022)Rhys H Parry, Yingjun Shang, Julian D J Sng, et al.
Environmental Research|March 1, 2021
Assessing the potential of unmanned aerial vehicle spraying of aqueous ozone as an outdoor disinfectant for SARS-CoV-2Simon Albert, Alberto A Amarilla, Ben Trollope, et al.
Nature Communications|September 26, 2025
A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicitySumma Bibby, James Jung, Yu Shang Low, et al.
Nature Communications|November 5, 2025
Author Correction: A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicitySumma Bibby, James Jung, Yu Shang Low, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Development and evaluation of an <sup>18</sup>F-labeled nanobody to target SARS-CoV-2's spike proteinSara Lopes van den Broek, Rocío García-Vázquez, Ida Vang Andersen, et al.
NPJ Vaccines|November 9, 2021
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A virusesChristopher L D McMillan, Stacey T M Cheung, Naphak Modhiran, et al.
Plos Pathogens|July 17, 2025
A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirusAndrew Young, Sharada Kolekar, Carlos Alvarez Mendoza, et al.
NPJ Vaccines|January 6, 2022
Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A virusesChristopher L D McMillan, Stacey T M Cheung, Naphak Modhiran, et al.
Pageof 8